Technology
Health
Biotechnology

Sunesis

$0.9799
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0299 (-3.15%) Today
+$0.0599 (6.51%) After Hours

Why Robinhood?

You can buy or sell Sunesis and other stocks, options, ETFs, and crypto commission-free!

About

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Read More The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Employees
29
Headquarters
South San Francisco, California
Founded
1998
Market Cap
35.60M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
325.19K
High Today
$0.99
Low Today
$0.875
Open Price
$0.98
Volume
340.14K
52 Week High
$3.51
52 Week Low
$0.20

Collections

Technology
Health
Biotechnology
Therapy
Research And Development
Pharmaceutical
Medical
US

News

Yahoo FinanceMar 15

Will Sunesis Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals. As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. SNSS. The stock has moved higher by 17.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider SNSS’s rece...

1,054
Seeking AlphaMar 7

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2018 Results - Earnings Call Transcript

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer Deepali Suri - Vice President, Clinical Operations Conference Call Participants Jim Birchenough - Wells Fargo Securities Hartaj Singh - Oppenheimer Kenneth Atkins - Cowen and Company Operator Welcome to the...

380
Yahoo FinanceMar 7

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018. Loss from operations for the three months and year ended December 31, 2018 was $5.8 million and $25.7 million. As of December 31, 2018, cash and cash equivalents totaled $13.7 million. Subsequent to the end of the quarter, the company raised $20 million in g...

19

Earnings

-$0.59
-$0.45
-$0.30
-$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.21 per share
Actual
-$0.16 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.